HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.

Abstract
In the antiphospholipid syndrome (APS), patients produce antiphospholipid antibodies (aPL) that promote thrombosis and adverse pregnancy outcomes. Current therapy with anticoagulation is only partially effective and associated with multiple complications. We previously discovered that aPL recognition of cell surface β2-glycoprotein I (β2-GPI) initiates apolipoprotein E receptor 2 (apoER2)-dependent signaling in endothelial cells and in placental trophoblasts that ultimately promotes thrombosis and fetal loss, respectively. Here we sought to identify a monoclonal antibody (mAb) to β2-GPI that negates aPL-induced processes in cell culture and APS disease endpoints in mice. In a screen measuring endothelial NO synthase (eNOS) activity in cultured endothelial cells, we found that whereas aPL inhibit eNOS, the mAb 1N11 does not, and instead 1N11 prevents aPL action. Coimmunoprecipitation studies revealed that 1N11 decreases pathogenic antibody binding to β2-GPI, and it blocks aPL-induced complex formation between β2-GPI and apoER2. 1N11 also prevents aPL antagonism of endothelial cell migration, and in mice it reverses the impairment in reendothelialization caused by aPL, which underlies the non-thrombotic vascular occlusion provoked by disease-causing antibodies. In addition, aPL inhibition of trophoblast proliferation and migration is negated by 1N11, and the more than 6-fold increase in fetal resorption caused by aPL in pregnant mice is prevented by 1N11. Furthermore, the promotion of thrombosis by aPL is negated by 1N11. Thus, 1N11 has been identified as an mAb that attenuates APS-related pregnancy complications and thrombosis in mice. 1N11 may provide an efficacious, mechanism-based therapy to combat the often devastating conditions suffered by APS patients.
AuthorsChieko Mineo, Lane Lanier, Eunjeong Jung, Samarpita Sengupta, Victoria Ulrich, Anastasia Sacharidou, Cristina Tarango, Olutoye Osunbunmi, Yu-Min Shen, Jane E Salmon, Rolf A Brekken, Xianming Huang, Philip E Thorpe, Philip W Shaul
JournalPloS one (PLoS One) Vol. 11 Issue 7 Pg. e0158757 ( 2016) ISSN: 1932-6203 [Electronic] United States
PMID27463336 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Nitric Oxide Synthase Type III
Topics
  • Antibodies, Monoclonal (immunology)
  • Antiphospholipid Syndrome (complications, prevention & control)
  • Cells, Cultured
  • Endothelium, Vascular (pathology)
  • Female
  • Fetal Resorption
  • Humans
  • Nitric Oxide Synthase Type III (metabolism)
  • Pregnancy
  • Pregnancy Complications (prevention & control)
  • Thrombosis (complications, prevention & control)
  • Trophoblasts (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: